Introduction: Tuberculosis remains a major public health problem in Senegal and, despite effective treatment, it frequently leaves respiratory sequelae that cause chronic morbidity. This study was conducted to determine the epidemiological, diagnostic, therapeutic and evolutionary aspects of post-tuberculosis respiratory sequelae. Methodology: Retrospective and descriptive study including patients with post-tuberculosis respiratory sequelae followed at the Saint-Jean de-Dieu Hospital in Thiès (Senegal). Results: Over a period of 63 months, we identified 133 cases of post-tuberculosis respiratory sequelae. There was a male predominance (67%) with a sex ratio of 2 and an average age of 51 years. In 83% of cases, a single episode of tuberculosis was sufficient to cause respiratory sequelae. Radiological abnormalities were mainly located in the lung parenchyma (61%) and were bilateral in 86% of cases. The main types of abnormalities were fibrous condensation blocks (15.03%), followed by emphysema (14.2%), pulmonary calcifications (13.53%) and fibrosis (9.02%). The complications found mainly included aspergillosis graft (32%) and chronic pulmonary heart disease (CPC) (32%). Conclusion: Post tuberculosis pulmonary sequelae remain common in vulnerable patients, with persistent symptoms and varied lesions. The lack of targeted functional assessment calls for more comprehensive prospective studies.

Congenital hypothyroidism is the first endocrinopathy found in newborns. it is a pathology subject to systematic screening in most countries around the world. Pendrid syndrome is a genetic cause of HC with thyroid gland in situ. It is a genetic condition in “SLC26A4 gene” (OMIM 605646) encoding Pendrin protein, and resulting in neurosensory deafness with congenital hypothyroidism and goiter. The presence of the 2 major symptoms; deafness and CH, consolidates the diagnosis while genetic sequencing is an element of confirmation. We report the observation of an infant who is a candidate for cochlear implant surgery and who was referred to us for hypothyroidism, in whom there is a history of severe pneumonia on bronchiectasis, which is a manifestation directly related to pendrid syndrome. An adequate thyroid biological and morphological evaluation, as well as screening for other malformations that may be associated with pendrid syndrome are extremely important in a holistic management of this genetic disease. To also recall the vital role that systematic screening for HC can play in preventing neurological disability among children, a procedure that is still not systematic in our country and that we fight to implement it.

Background: Albuminuria and poor glycemic control drive kidney and cardiovascular risk in type 2 diabetes. Dapagliflozin lowers glucose and reduces albuminuria through renal mechanisms. Evidence from trials is strong, yet data from routine care in Dubai are limited. Objective: To evaluate changes in urine albumin-to-creatinine ratio and HbA1c over 24 months after dapagliflozin initiation in Dubai primary care. Methods: We performed a retrospective longitudinal study using the Salama electronic record across Dubai Health Authority clinics. Adults with type 2 diabetes who started dapagliflozin contributed measurements at baseline, 3, 6, 12 and 24 months. The primary outcome was change in UACR. Secondary outcome was change in HbA1c. Paired comparisons used baseline vs each follow-up. Longitudinal trends used repeated measures analyses. Prespecified subgroups assessed UACR by age group and HbA1c by sex, age and metformin use. Results: Two hundred adults were included. Mean age was 61 years, range 21 to 87 years. UACR fell from 123 mg/g at baseline to 52 mg/g at 24 months, a 57.7% reduction, p<0.001. The decline appeared by 3 months and progressed at each visit. The 24-month UACR was 52 mg/g with 95% CI 50 to 54. HbA1c decreased from 8.2% to 6.8% at 24 months, p<0.001, with 24-month HbA1c 95% CI 6.7 to 6.9. By age subgroup, UACR reduction at 12 months ranged from 25% in patients 40–50 years to 50% in those 70–80 years and at 24 months ranged from 35% to 70%. HbA1c improved across subgroups. Larger absolute HbA1c drops were seen in younger patients and in those treated with metformin at baseline. HbA1c patterns by sex were similar. Conclusion: In Dubai primary care, dapagliflozin was associated with large and sustained reductions in albuminuria and a meaningful fall in HbA1c over 24 months. Early change at 3 months and continued improvement through 2 years support routine monitoring at these intervals. These results suggest that expected renal and glycemic benefits can be achieved in day-to-day care across diverse patients.